14 December 2018

Grünenthal and OnDosis team up for individualised dosing of oral drugs in pain management to increase patient safety

Life science startup OnDosis signs its first global development and licensing agreement for their innovative technology. Grünenthal expands its portfolio with an innovative technology for individualised dosing.

Read more

4 December 2018

OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

Swedish life science company, OnDosis, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development of an ADHD treatment for the US market.

Read more

18 October 2017

Introducing OnDosis, a new life science company

Based on innovative technology developed by AstraZeneca, OnDosis is a new, Gothenburg-based, life science company with the mission to simplify dosing and enable personalised administration of medicines by connecting medicines, devices and digital health to benefit patients. AstraZeneca and GU Ventures have founded OnDosis together with entrepreneurial CEO, Martin Olovsson.

Read more

4 Dec 2018

Recipharm and OnDosis sign cooperation agreement

(In Swedish)

Read more

4 Dec 2018

OnDosis enters a collaboration regarding ADHD treatment

(In Swedish)

Read more

4 Dec 2018

OnDosis, Recipharm in ADHD Alliance

Read more

Press material

Download images and logotype approved for press use here.

Don’t miss a thing

Development is fast-moving at OnDosis. Sign up for our newsletter and we’ll make sure to keep you up to date with all our important news.